Published in Ann Intern Med on June 02, 2009
Metabolic syndrome: definitions and controversies. BMC Med (2011) 3.80
Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) (2010) 1.90
Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab (2011) 1.64
Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension (2014) 1.56
Diabetes mellitus and vascular disease. Hypertension (2013) 1.47
Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab (2010) 1.23
Epithelial Na+ channel (ENaC), hormones, and hypertension. J Biol Chem (2010) 1.22
Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol (2010) 1.13
Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis (2010) 1.12
Exercise in the metabolic syndrome. Oxid Med Cell Longev (2012) 1.11
Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis (2011) 1.10
Skeletal muscle insulin resistance in endocrine disease. J Biomed Biotechnol (2010) 1.09
Activity, energy intake, obesity, and the risk of incident kidney stones in postmenopausal women: a report from the Women's Health Initiative. J Am Soc Nephrol (2013) 1.09
Perivascular adipose tissue-derived adiponectin activates BK(Ca) channels to induce anticontractile responses. Am J Physiol Heart Circ Physiol (2013) 1.08
Aldosterone and arterial hypertension. Nat Rev Endocrinol (2009) 1.06
Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens (2010) 1.06
Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol (2011) 1.05
Exploring metabolic dysfunction in chronic kidney disease. Nutr Metab (Lond) (2012) 1.04
Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens (2011) 1.03
Oxidative stress in the cardiorenal metabolic syndrome. Curr Hypertens Rep (2012) 1.02
Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol (2011) 1.02
Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart Study. Diabetes Care (2013) 1.02
Hypertension and insulin resistance. Hypertension (2009) 0.98
Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans. J Clin Endocrinol Metab (2014) 0.97
Indices of obesity and cardiometabolic risk. Hypertension (2011) 0.92
Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension (2016) 0.90
A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension. J Hum Hypertens (2013) 0.90
Current challenges in the clinical management of hypertension. Nat Rev Cardiol (2011) 0.89
Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome. Int J Hypertens (2011) 0.89
Deregulation of adipokines related to target organ damage on resistant hypertension. J Hum Hypertens (2013) 0.88
Endothelial Mineralocorticoid Receptor Deletion Prevents Diet-Induced Cardiac Diastolic Dysfunction in Females. Hypertension (2015) 0.88
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. Regul Pept (2012) 0.87
Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. PLoS One (2012) 0.86
Blood spotlight on leukocytes and obesity. Blood (2013) 0.85
Interaction between Adiponectin and Aldosterone. Cardiorenal Med (2011) 0.85
Role of mitogen-activated protein kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndrome. Mediators Inflamm (2013) 0.85
Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Diabetologia (2013) 0.84
Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis (2015) 0.84
Effects of aldosterone on insulin sensitivity and secretion. Steroids (2014) 0.83
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. Metabolism (2013) 0.82
Practical recommendations for treatment of hypertension in older patients. Vasc Health Risk Manag (2010) 0.82
Overnutrition and the Cardiorenal Syndrome: Use of a Rodent Model to Examine Mechanisms. Cardiorenal Med (2011) 0.82
Mineralocorticoids stimulate the activity and expression of renal H+,K+-ATPases. J Am Soc Nephrol (2010) 0.82
The metabolic syndrome and risk of chronic kidney disease: pathophysiology and intervention strategies. J Nutr Metab (2012) 0.81
Drug mechanisms to help in managing resistant hypertension in obesity. Curr Hypertens Rep (2010) 0.81
The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy. Hypertens Res (2015) 0.81
Aldosterone and Risk for Insulin Resistance. Hypertension (2011) 0.81
Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure? Heart Fail Rev (2015) 0.80
Possible Link between Metabolic Syndrome and Chronic Kidney Disease in the Development of Cardiovascular Disease. Cardiol Res Pract (2010) 0.80
Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD. Nat Rev Cardiol (2009) 0.79
Association of aldosterone and cortisol with cardiovascular risk factors in prehypertension stage. Int J Hypertens (2012) 0.79
Na+-sensitive elevation in blood pressure is ENaC independent in diet-induced obesity and insulin resistance. Am J Physiol Renal Physiol (2016) 0.79
Increased aldosterone among HIV-infected women with visceral fat accumulation. AIDS (2009) 0.79
Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. J Am Geriatr Soc (2010) 0.79
A case of primary aldosteronism revealed after renal transplantation. Nat Rev Nephrol (2010) 0.78
The development of hypertension and hyperaldosteronism in a rodent model of life-long obesity. Endocrinology (2012) 0.78
Genome-wide meta-analyses of plasma renin activity and concentration reveal association with the kininogen 1 and prekallikrein genes. Circ Cardiovasc Genet (2014) 0.78
The ADMA-Metformin Hypothesis: Linking the Cardiovascular Consequences of the Metabolic Syndrome and Type 2 Diabetes. Cardiorenal Med (2011) 0.77
Aldosterone and glomerular filtration--observations in the general population. BMC Nephrol (2014) 0.77
Changes in morphology and function of adrenal cortex in mice fed a high-fat diet. Int J Obes (Lond) (2014) 0.77
Developments in renal pharmacogenomics and applications in chronic kidney disease. Pharmgenomics Pers Med (2014) 0.77
Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension. Eur J Clin Pharmacol (2013) 0.77
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients. Am J Ther (2013) 0.76
Genetics of resistant hypertension: a novel pharmacogenomics phenotype. Curr Hypertens Rep (2015) 0.76
Adipokines: another link between obesity and hypertension. J Hum Hypertens (2014) 0.75
The McKittrick-Wheelock syndrome: a rare cause of curable diabetes. Endocrinol Diabetes Metab Case Rep (2016) 0.75
Aldosterone induces clonal β-cell failure through glucocorticoid receptor. Sci Rep (2015) 0.75
World Congress on the Insulin Resistance Syndrome, 2009: the kidney, the liver, and insulin resistance. Diabetes Care (2010) 0.75
Higher blood aldosterone level in metabolic syndrome is independently related to adiposity and fasting plasma glucose. Cardiovasc Diabetol (2015) 0.75
Association of cardiac NT pro-β-type natriuretic peptide with metabolic and endothelial risk factors in young obese hypertensive patients: a perspective on the hypothalamic pituitary adrenal axis activation. Diabetol Metab Syndr (2016) 0.75
RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes. J Diabetes Res (2013) 0.75
Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation end-products in rhesus macaques with spontaneous hypertensive metabolic syndrome. Sci Rep (2016) 0.75
Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis. Exp Ther Med (2017) 0.75
Elevated levels of circulating angiotensin converting enzyme in patients with hepatoportal sclerosis. Dig Dis Sci (2011) 0.75
[The role of aldosterone in hypertension]. Wien Klin Wochenschr (2010) 0.75
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
Mechanisms linking obesity with cardiovascular disease. Nature (2006) 9.07
Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation (2004) 7.77
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
Role of mitochondrial dysfunction in insulin resistance. Circ Res (2008) 3.45
Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension (2002) 2.46
Effects of aldosterone on the vasculature. Hypertension (2006) 2.32
[Constitution of aldosterone, a new mineralocorticoid]. Experientia (1954) 2.28
The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med (1981) 2.05
Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med (1965) 1.81
Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens (2004) 1.75
Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A (2003) 1.74
Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation (2008) 1.73
Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J (2007) 1.72
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol (2007) 1.71
Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension (2007) 1.70
50th anniversary of aldosterone. J Clin Endocrinol Metab (2003) 1.70
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med (2008) 1.68
Aldosterone and vascular inflammation. Hypertension (2008) 1.65
A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens (2007) 1.57
Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension (2006) 1.57
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol (2006) 1.56
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol (2006) 1.49
Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab (2006) 1.47
Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension (2005) 1.47
Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension (2006) 1.40
Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension (2007) 1.40
Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab (2005) 1.36
Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens (2003) 1.35
Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol (1985) (2002) 1.35
Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther (1987) 1.31
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med (2006) 1.31
Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis (2001) 1.31
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology (2007) 1.31
Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab (2008) 1.22
Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension (2004) 1.17
Metabolic risk factors and renal disease. Kidney Int (2007) 1.14
Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension (2007) 1.14
Treating resistant hypertension with a neglected old drug. Hypertension (2007) 1.13
Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens (2007) 1.10
Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res (2004) 1.08
Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 1.04
Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation (2003) 1.03
Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res (2007) 1.01
Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension (2008) 0.99
Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis (2008) 0.96
Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology (1993) 0.96
Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens (2007) 0.94
Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. Am J Physiol (1992) 0.93
Phenotypic consequences of variation across the aldosterone synthase and 11-beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study. Clin Endocrinol (Oxf) (2007) 0.87
Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr (2008) 0.87
Fat tissue metabolism and adrenal steroid secretion. Curr Hypertens Rep (2006) 0.85
Hypertension and the cardiometabolic syndrome. J Clin Hypertens (Greenwich) (2005) 0.83
Renal injury in extreme obesity: the important role of aldosterone. Kidney Int (2008) 0.81
Aldosterone excess, hypertension, and chromosome 7p22: evidence continues to mount. Hypertension (2007) 0.78
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) (2010) 1.90
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol (2007) 1.71
Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int (2012) 1.66
Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis (2004) 1.56
Redox control of renal function and hypertension. Antioxid Redox Signal (2008) 1.45
No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int (2013) 1.38
The Role of Overweight and Obesity in the Cardiorenal Syndrome. Cardiorenal Med (2011) 1.35
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension (2010) 1.32
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology (2007) 1.31
Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab (2008) 1.22
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol (2009) 1.18
Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology (2013) 1.15
Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Am J Physiol Regul Integr Comp Physiol (2011) 1.12
Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology (2007) 1.11
Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities. J Cardiometab Syndr (2008) 1.06
Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol (2005) 1.04
Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology (2010) 1.03
The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney. Cardiorenal Med (2011) 1.01
Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism (2009) 1.00
Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. Am J Physiol Renal Physiol (2006) 0.99
Inhibition of nitric oxide synthase evokes central sympatho-excitation in healthy humans. J Physiol (2009) 0.98
Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP). Curr Diab Rep (2011) 0.98
Hypertension and insulin resistance. Hypertension (2009) 0.98
The cardiometabolic syndrome as a cardiovascular risk factor. Am J Med Sci (2005) 0.95
Obesity, Diabetes, the Cardiorenal Syndrome, and Risk for Cancer. Cardiorenal Med (2012) 0.94
Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol (2005) 0.93
The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep (2010) 0.93
Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology (2014) 0.93
Indices of obesity and cardiometabolic risk. Hypertension (2011) 0.92
The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci (2005) 0.92
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens (2012) 0.91
Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats. Am J Nephrol (2010) 0.90
Antihypertensive medications and their effects on lipid metabolism. Curr Diab Rep (2008) 0.88
Possible Mechanisms of Local Tissue Renin-Angiotensin System Activation in the Cardiorenal Metabolic Syndrome and Type 2 Diabetes Mellitus. Cardiorenal Med (2011) 0.87
DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity (Silver Spring) (2014) 0.87
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol (2012) 0.87
Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr (2006) 0.87
Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives. Endocrinol Metab Clin North Am (2013) 0.86
DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes. Cardiorenal Med (2013) 0.86
Acute Cardiac Tamponade: An Unusual Cause of Acute Renal Failure. Cardiorenal Med (2012) 0.86
Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2012) 0.86
The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. Cardiorenal Med (2011) 0.85
Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag (2009) 0.85
Hypertension in Cardiovascular and Kidney Disease. Cardiorenal Med (2011) 0.85
The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program. J Clin Endocrinol Metab (2012) 0.84
Regulation of Overnutrition-Induced Cardiac Inflammatory Mechanisms. Cardiorenal Med (2012) 0.84
Novel role for the incretins in blood pressure regulation. Curr Opin Nephrol Hypertens (2012) 0.84
Hypertension and the cardiometabolic syndrome. J Clin Hypertens (Greenwich) (2005) 0.83
Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. Transl Res (2009) 0.83
Hypertension and chronic kidney disease progression: why the suboptimal outcomes? Am J Med (2012) 0.83
Resistant hypertension in the high-risk metabolic patient. Curr Diab Rep (2011) 0.83
Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. Metabolism (2011) 0.83
Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update. Curr Diab Rep (2007) 0.82
The Association between Parathyroid Hormone Levels and Hemoglobin in Diabetic and Nondiabetic Participants in the National Kidney Foundation's Kidney Early Evaluation Program. Cardiorenal Med (2013) 0.82
Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. Am J Nephrol (2006) 0.82
The Role of Team-Based Care Involving Pharmacists to Improve Cardiovascular and Renal Outcomes. Cardiorenal Med (2012) 0.82
Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus. J Clin Pharmacol (2002) 0.80
Type 2 diabetes in older people; the importance of blood pressure control. Curr Cardiovasc Risk Rep (2013) 0.79
Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich) (2009) 0.79
Therapy of obese patients with cardiovascular disease. Curr Opin Pharmacol (2013) 0.79
Dysglycemia but not lipids is associated with abnormal urinary albumin excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP). BMC Nephrol (2012) 0.78
Obesity and heart failure as a mediator of the cerebrorenal interaction. Contrib Nephrol (2013) 0.78
Relationship between erythropoietin administration and alterations of renin-angiotensin-aldosterone. J Renin Angiotensin Aldosterone Syst (2006) 0.78
Chronic kidney disease and cardiovascular risk. J Am Soc Hypertens (2010) 0.78
Use of Metformin in Patients with Kidney and Cardiovascular Diseases. Cardiorenal Med (2011) 0.78
Basic science: Pathophysiology: the cardiorenal metabolic syndrome. J Am Soc Hypertens (2014) 0.78
Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. Expert Opin Pharmacother (2005) 0.77
Over-nutrition contributes to tubulointerstitial fibrosis by targeting nutrient-sensing kinases: role for the mTOR/S6K pathway. Cell Cycle (2012) 0.77
Hypoglycemia: A Possible Link between Insulin Resistance, Metabolic Dyslipidemia, and Heart and Kidney Disease (the Cardiorenal Syndrome). Cardiorenal Med (2011) 0.77
An Emerging Role for Understanding Orthostatic Hyp'er'tension in the Cardiorenal Syndrome. Cardiorenal Med (2011) 0.77
Outcomes of carotid revascularization in patients with chronic kidney disease. Adv Chronic Kidney Dis (2008) 0.77
Hyperkalemia as a constraint to therapy with combination Renin-Angiotensin system blockade: the elephant in the room. J Clin Hypertens (Greenwich) (2009) 0.76
Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics. Am J Hypertens (2004) 0.76
Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II. Mol Cell Endocrinol (2013) 0.76
Aldosterone and large artery vessels. Hypertension (2006) 0.76
Is it time to target prehypertension. Cardiovasc Ther (2010) 0.75
A decade after the KDOQI CKD guidelines: impact on the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2012) 0.75
Micro vs. macrovascular reactivity in insulin resistance: the debate reignited. Am J Hypertens (2010) 0.75
Angiotensin type 1 receptor resistance to blockade in the opossum proximal tubule cell due to variations in the binding pocket. Am J Physiol Renal Physiol (2013) 0.75
Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. J Hypertens (2017) 0.75
Metabolic impact of adding a thiazide diuretic to captopril. Hypertension (2013) 0.75
The kaliuretic impact of cicletanine compared to hydrochlorothiazide. J Hypertens (2012) 0.75
Chronic kidney disease and the cardiometabolic syndrome. J Clin Hypertens (Greenwich) (2006) 0.75
Obesity, insulin resistance, and nocturnal systolic blood pressure. Hypertension (2008) 0.75
Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins. J Clin Lipidol (2008) 0.75
Initial choice of antihypertensive on long-term cardiovascular outcomes in CKD. Clin J Am Soc Nephrol (2012) 0.75
Role of Growth Hormone Deficiency and Treatment in Chronic Kidney Disease. Cardiorenal Med (2011) 0.75
Diabetes: Aspirin and prevention of diabetes still a topic of debate. Nat Rev Endocrinol (2009) 0.75
Novel therapeutics in hypertension and kidney disease. Curr Opin Nephrol Hypertens (2015) 0.75
Arrhythmias and sudden cardiac death in hemodialysis patients. Temporal profile, electrolyte abnormalities, and potential targeted therapies. Nephrol News Issues (2016) 0.75
OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD. J Hypertens (2016) 0.75
Novel interventions for resistant hypertension. Curr Opin Nephrol Hypertens (2013) 0.75
Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy. J Clin Pharmacol (2004) 0.75
Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be? Clin J Am Soc Nephrol (2006) 0.75
The use of calcium antagonists in the treatment of hypertensive persons with kidney disease. Curr Hypertens Rep (2002) 0.75
Emerging therapeutic options for managing diabetic kidney disease. Curr Opin Nephrol Hypertens (2017) 0.75
The use and interpretation of troponin in ESRD patients. Semin Dial (2014) 0.75
OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD. J Hypertens (2016) 0.75